Feedback / Questions
A2B530 - A2 Biotherap
https://www.businesswire.com/news/home/20240304501299/en/A2-Bio-Receives-FDA-Orphan-Drug-Designation-for-Novel-Cell-Therapy-Program-A2B530-in-Colorectal-Cancer
Mar 4, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next